Almirall licenses COPD agent to Forest
Spanish pharma Almirall (treatments for respiratory and autoimmune diseases) licensed Forest Laboratories US sales and marketing rights to its Phase III candidate LAS34273 for chronic obstructive pulmonary disease (COPD).
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.